- Home
- MNOV vs VIGL Comparison
MNOV vs VIGL Comparison
Compare MNOV & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- VIGL
- Stock Information
- Founded
- MNOV 2000
- VIGL 2020
- Country
- MNOV United States
- VIGL United States
- Employees
- MNOV N/A
- VIGL N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- VIGL Health Care
- Exchange
- MNOV Nasdaq
- VIGL Nasdaq
- Market Cap
- MNOV 89.8M
- VIGL 89.3M
- IPO Year
- MNOV 2005
- VIGL 2022
- Fundamental
- Price
- MNOV $1.83
- VIGL $3.03
- Analyst Decision
- MNOV Strong Buy
- VIGL Strong Buy
- Analyst Count
- MNOV 1
- VIGL 5
- Target Price
- MNOV $9.00
- VIGL $21.00
- AVG Volume (30 Days)
- MNOV 21.3K
- VIGL 642.5K
- Earning Date
- MNOV 02-19-2025
- VIGL 03-25-2025
- Dividend Yield
- MNOV N/A
- VIGL N/A
- EPS Growth
- MNOV N/A
- VIGL N/A
- EPS
- MNOV N/A
- VIGL N/A
- Revenue
- MNOV N/A
- VIGL N/A
- Revenue This Year
- MNOV N/A
- VIGL N/A
- Revenue Next Year
- MNOV N/A
- VIGL N/A
- P/E Ratio
- MNOV N/A
- VIGL N/A
- Revenue Growth
- MNOV N/A
- VIGL N/A
- 52 Week Low
- MNOV $1.12
- VIGL $1.49
- 52 Week High
- MNOV $2.55
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- MNOV 43.26
- VIGL 77.87
- Support Level
- MNOV $1.75
- VIGL $2.71
- Resistance Level
- MNOV $2.00
- VIGL $2.95
- Average True Range (ATR)
- MNOV 0.08
- VIGL 0.21
- MACD
- MNOV -0.00
- VIGL 0.03
- Stochastic Oscillator
- MNOV 27.59
- VIGL 86.18
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.